Immunotherapy Advances

graphical abstract for Strategies to overcome low MHC-I expression in paediatric and adult tumours

🧬 Low MHC-I expression can help tumours evade the immune system.

Discover strategies to boost MHC-I and improve immunotherapy in paediatric and adult cancers. 🔬

Read: https://bit.ly/45vtfmp

#Immunotherapy #CancerResearch #MHCI

graphical abstract for Tumour-reactive plasma cells in antitumour immunity: current insights and future prospects

💡 Tumour-reactive plasma cells are emerging as powerful players in cancer immunotherapy!

Explore their role in antibody-based, personalized treatments. 🔬

Read: https://bit.ly/3SVZsMC

#Immunotherapy #CancerResearch #PlasmaCells

graphical abstract of Harnessing natural killer cell effector function against cancer

💥Open Access review: NK cells as cancer fighters!

From CAR-NK cells to checkpoint inhibitors, explore cutting-edge strategies to harness NK-cell immunity. 🔬

Read: https://bit.ly/4j8dKEW

#Immunotherapy #NKcells #CancerResearch

Could CD200R blockade enhance PD-1 therapy?

A humanised mouse study found limited benefit in colorectal & lung cancer, but points to potential in CD200⁺ tumours.

🔗 https://bit.ly/4pdAtDw

#Immunotherapy #CancerResearch

Exploring the role of DC3s in solid tumours! These dendritic cells can boost anti-tumour immunity or contribute to immunosuppression depending on the TME.

Discover their potential for targeted therapies 👉 https://bit.ly/3T2blRg

#EMDS2025 #Immunotherapy #CancerResearch

TAMs drive tumour progression, metastasis & therapy resistance.

Targeting their surface receptors may unlock new cancer immunotherapy strategies, insights for #EMDS2025

🔗 https://bit.ly/4i95qnm

Could JAK inhibitors be a treatment for STAT3 gain-of-function?

Study shows symptom improvement in patients with this rare immune disorder.

Read here🔗 https://bit.ly/4p7Vxer

#Immunotherapy

⏳ Last chance! Submit your research on immunotherapies for inborn errors of immunity to our Special Collection before the end of September.

Submit here: https://bit.ly/4p96dJA

#Immunology

It's the final day of Cancer Immunology: Advances & Therapeutic Application, don’t miss our journals manager Laura Franklin giving a talk at 11:00 AM today!

Learn more about publishing opportunities and journal initiatives.

#CancerImmunology #Immunotherapy

Are you attending Cancer Immunology: Advances & Therapeutic Application and working on cancer vaccines?
Share your latest research in our Special Collection on global advances, personalised or off-the-shelf vaccines, clinical trials & more.

Submit here: https://bit.ly/4mPbW64

Attending Cancer Immunology: Advances & Therapeutic Application?

Come and visit us at our booth to learn more about our journals, upcoming special collections, and opportunities to publish! #CancerImmunology #Immunology

NLRP3 inflammasome activation in sensory neurons drives chronic inflammatory & osteoarthritis pain.

Blocking this pathway may offer a route to new treatments.

Read more🔗 https://bit.ly/3UX7Tbz

#ChronicPain #Immunology

Working on targeted therapies for inborn errors of immunity?

Our Special Collection on genetics-guided immunotherapy closes at the end of this month, submit your research today!

Learn more: https://bit.ly/4p96dJA

🚀 Going viral against #Glioblastoma!

Discover how oncolytic viruses are reshaping the immune landscape of GBM, boosting therapy response & offering new hope.

Open Access 👉 https://bit.ly/3UMBhkw #Immunotherapy #CancerResearch

High-affinity TCR bispecific (ImmTAC®) redirects T cells to efficiently kill PRAME+ tumor cells across multiple cancers. Combination with PD-1 blockade may enhance activity.

By Ribeiro et al.

🔗 https://bit.ly/40o5kT8

#Immunotherapy #CancerResearch #PRAME

💉 During #ImmunisationAwarenessMonth, a timely reminder: mRNA COVID-19 vaccines (Pfizer & Moderna) remain highly effective at preventing hospitalisation (84–86%), even with variant challenges.

🔗 https://bit.ly/43rUWvP

#Vaccineswork #immunology

💉 Cancer vaccines are regaining momentum with advances in neoantigen science, tumour mutational burden & mRNA technology.

A deeper understanding of dendritic cells and immune mechanisms is key to unlocking their full potential. 🚀

#ImmunisationAwarenessMonth

🔗 https://bit.ly/4cefxGm

Why are paediatric tumours less responsive to immunotherapy?

One reason: MHC-I downregulation. Restoring it could make tumour cells visible again to CD8 T cells.

🔗 https://bit.ly/45vtfmp

Smallpox vaccines provide important cross-protection against Mpox. Evidence from past outbreaks informed the use of the MVA–BN vaccine during 2022, highlighting how immunisation strengthens preparedness for emerging threats.

#NationalImmunisationAwarenessMonth

👉 https://bit.ly/4jSbodz

Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment graphical abstract

Bispecific T-cell engagers (BiTEs) redirect T-cells to attack tumors, but their power is often limited by immune checkpoints & suppressive microenvironments.

💡 Combination strategies with checkpoint inhibitors, chemo, or oncolytic viruses could boost effectiveness.

👉 https://bit.ly/4oKabbt

🌟 Researchers in cancer immunology: showcase your work in our Special Collection: Cancer Vaccines Global Advances!

Submit studies, reviews, or clinical updates on personalized & off-the-shelf vaccines.

Deadline: Dec 2025.

#CancerResearch #Immunotherapy

Did you know? 🩺 Patients on immune checkpoint inhibitors can develop inverse psoriasis, often mistaken for fungal infections.

Early recognition by oncologists & dermatologists is key to better care. 🧴🩹

#NationalPsoriasisMonth #Psoriasis

🔗 https://bit.ly/4lw91iq

Liu et al. show that SMAC mimetics + IFNγ can reprogram human macrophages to phagocytose live pancreatic & breast cancer cells, revealing a TNFα-driven feedback loop that sustains this activity.

Read now🔗 https://bit.ly/4mBGMix

#Immunotherapy #CancerResearch

📅 August is #NationalPsoriasisMonth 🧬

Study finds similar immune responses in chronic plaque psoriasis patients on Humira® whether they stayed on it or switched with AVT02, supporting interchangeability.

🔗 https://bit.ly/3J8pESs

Tumour-reactive plasma cells (TRPCs) are emerging as potent players in cancer immunotherapy 🧬🧪

Chen et al explore their potential, challenges in neoantigen targeting, and prospects for personalised therapy.

📖 https://bit.ly/3SVZsMC

#Immunotherapy #CancerResearch

🧠 Can viruses turn the tide in glioblastoma treatment?

Oncolytic virus therapy shows promise in reshaping the tumour microenvironment and boosting immune response in GBM. Explore the latest insights and clinical trial findings: https://bit.ly/3UMBhkw

#Immunotherapy

Studying cancer vaccines? 🎯

Submit your latest research to our Cancer Vaccines Global Advances Special Collection!

Showcase personalized & off-the-shelf vaccines, clinical trials & more.

Deadline: Dec 2025

Learn more & submit: https://bit.ly/45mr1m8

#Immunotherapy

🔥 One of our most read articles!

Discover the unique role of DC3 dendritic cells in shaping immune responses within solid tumours and their impact on cancer therapy.

📖 Read more: https://bit.ly/3T2blRg

#CancerImmunology #DC3 #Immunotherapy

New open-access study reveals two distinct ways anti-CTLA-4 therapy can boost anti-tumour immunity, and highlights the surprising role of soluble CTLA-4 as both a challenge and a potential therapeutic tool.

🔗 https://bit.ly/4k6jcZj

#Immunotherapy #CTLA4 #CancerResearch

🚀 Immunobridging trials could fast-track cancer vaccine development by using immunological surrogates instead of lengthy Phase III trials.

Challenges remain in identifying reliable biomarkers, especially within the tumour microenvironment.

Read now: https://bit.ly/4faVpX0